ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,726.10
0.13%
US Tech 100
19,407.60
0.45%
다우존스 지수
42,114.88
-0.02%
Bitcoin
63,748.28
0.66%
Registration Strip Icon for charts 실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Kintara Therapeutics Inc (KTRA)

  7. Kintara Therapeutics Inc (KTRA) 뉴스

KTRA

Kintara Therapeutics (KTRA)

Kintara Therapeutics Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:KTRA
일자시간출처헤드라인심볼기업
2024/09/2421:35Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/2421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/09/2105:20Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/2105:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/09/2022:25PR Newswire (US)Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024NASDAQ:KTRAKintara Therapeutics Inc
2024/09/1821:40Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1821:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1821:30PR Newswire (US)Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA BiosciencesNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1821:30PR Newswire (US)Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA BiosciencesNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1121:40Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1121:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1121:30PR Newswire (US)Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical StudyNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1005:10Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/1005:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/09/0921:30PR Newswire (US)Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc.NASDAQ:KTRAKintara Therapeutics Inc
2024/09/0406:25Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/09/0406:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/08/1922:10Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/08/1922:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/08/1922:00PR Newswire (US)TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor CancerNASDAQ:KTRAKintara Therapeutics Inc
2024/08/1413:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:KTRAKintara Therapeutics Inc
2024/08/1306:01Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
2024/08/0906:30Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
2024/07/2006:03Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:KTRAKintara Therapeutics Inc
2024/07/1306:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/07/0819:45Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
2024/07/0819:40Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KTRAKintara Therapeutics Inc
2024/07/0819:30PR Newswire (US)TuHURA Biosciences Enters into Exclusivity and Right of First Offer Agreement for Kineta, Inc.'s KVA12123 Novel anti-VISTA Checkpoint InhibitorNASDAQ:KTRAKintara Therapeutics Inc
2024/07/0121:35PR Newswire (US)Kintara Therapeutics and TuHURA Biosciences Provide Update on Recent Corporate and Clinical Advancements and Outline Near Term MilestonesNASDAQ:KTRAKintara Therapeutics Inc
2024/06/1405:10Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:KTRAKintara Therapeutics Inc
 검색 관련기사 보기:NASDAQ:KTRA

최근 히스토리

COIN
ADAUSD
Cardano
USI
USTECH100
US Tech 100
COIN
DOGEUSD
Dogecoin
USOTC
ADDYY
Adidas (QX)
COIN
ETHUSD
Ethereum
NYSE
KO
Coca Cola
NYSE
XOM
Exxon Mobil
AMEX
XLV
Health Care Select Sector
PM
XAUUSD
Gold vs US Dollar
NASDAQ
AAPL
Apple
NYSE
BAC
Bank of America
CCOM
US100
US Tech 100
AMEX
SPY
SPDR S&P 500
NYSE
DIS
Walt Disney
COIN
SOLUSD
Solana
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

대한민국
회사 소개
사업
Popular
앱 받기
App Store
Google Play

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유